Labcorp (LH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting opened with thanks to the team and a focus on strong financial performance and strategic priorities for 2025.
Board members, senior officers, and representatives from Deloitte & Touche LLP were introduced.
Agenda included election of directors, advisory vote on executive compensation, and ratification of the accounting firm.
Financial performance review
Noted strong financial performance in 2025 and progress toward strategic priorities, emphasizing disciplined execution and long-term growth.
Board and executive committee updates
Full list of directors and senior officers present was provided, highlighting leadership continuity.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Labcorp
- Q1 2026 delivered 5.8% revenue growth, higher margins, and raised guidance for the full year.LH
Q1 20265 May 2026 - 2025 saw record revenues, board refreshment, and strong ESG and pay-for-performance alignment.LH
Proxy filing10 Apr 2026 - Vote on directors, executive pay, and auditor at the May 2026 Annual Meeting.LH
Proxy filing10 Apr 2026 - 2025 saw 7.2% revenue growth and strong EPS gains, with positive 2026 guidance.LH
Q4 202517 Feb 2026 - Q2 revenue up 6.2% to $3.22B, with higher guidance and expanded capital returns.LH
Q2 20242 Feb 2026 - Growth driven by specialty testing, global expansion, and accretive acquisitions, with raised 2024 guidance.LH
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Inorganic growth accelerates, core businesses remain strong, and Invitae integration is on track.LH
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 7.4% year-over-year, with strong Diagnostics and Biopharma growth.LH
Q3 202418 Jan 2026 - Specialty testing, M&A, and AI drive growth, with regulatory changes closely monitored.LH
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026